MCID: SLV002
MIFTS: 60

Salivary Gland Cancer

Categories: Oral diseases, Cancer diseases, Gastrointestinal diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Salivary Gland Cancer

MalaCards integrated aliases for Salivary Gland Cancer:

Name: Salivary Gland Cancer 12 52 41 14
Malignant Neoplasm of Salivary Gland 12 69
Malignant Tumor of the Major Salivary Gland 12
Malignant Neoplasm of Major Salivary Gland 12
Malignant Neoplasm of Salivary Gland Duct 12
Malignant Tumor of the Salivary Gland 12
Salivary Gland Neoplasms 69
Salivary Gland Neoplasm 29

Classifications:



External Ids:

Disease Ontology 12 DOID:8850
ICD10 33 C08
ICD9CM 35 142.8
SNOMED-CT 64 187648003
UMLS 69 C0153362

Summaries for Salivary Gland Cancer

MedlinePlus : 41 your salivary glands make saliva - sometimes called spit - and empty it into your mouth through openings called ducts. saliva makes your food moist, which helps you chew and swallow. it helps you digest your food. it also cleans your mouth and contains antibodies that can kill germs. salivary gland cancer is a type of head and neck cancer. it is rare. it may not cause any symptoms, or you could notice a lump in your ear, cheek, jaw, lip, or inside the mouth fluid draining from your ear trouble swallowing or opening the mouth widely numbness, weakness, or pain in your face doctors diagnose salivary gland cancer using a physical exam, imaging tests, and a biopsy. treatment can include surgery, radiation therapy, and/or chemotherapy. nih: national cancer institute

MalaCards based summary : Salivary Gland Cancer, also known as malignant neoplasm of salivary gland, is related to salivary gland cancer, adult and salivary gland cancer, childhood, and has symptoms including halitosis and snoring. An important gene associated with Salivary Gland Cancer is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Bleomycin and Anti-Bacterial Agents have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, lung and testes, and related phenotypes are Decreased viability with paclitaxel and cellular

Disease Ontology : 12 An oral cavity cancer that is located in the salivary gland.

Wikipedia : 72 Salivary gland cancer is a cancer that forms in tissues of a salivary gland. The salivary glands are... more...

Related Diseases for Salivary Gland Cancer

Diseases in the Salivary Gland Cancer family:

Salivary Gland Cancer, Adult

Diseases related to Salivary Gland Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
id Related Disease Score Top Affiliating Genes
1 salivary gland cancer, adult 12.3
2 salivary gland cancer, childhood 12.0
3 brooke-spiegler syndrome 11.0
4 pleomorphic adenoma 11.0
5 mucoepidermoid carcinoma 10.9
6 sublingual gland cancer 10.9
7 parotid gland cancer 10.9
8 infiltrating ureter transitional cell carcinoma 10.8 EGFR ERBB2
9 bannayan-riley-ruvalcaba syndrome 10.7 EGFR PTEN
10 skin sarcoma 10.6 EGFR ERBB2
11 facial arteriovenous malformation 10.6 MMP2 MMP9
12 juvenile astrocytoma 10.6 EGFR PPARG PTEN
13 cleft lip palate dysmorphism kumar type 10.6 EGFR MET PTEN
14 rectum kaposi's sarcoma 10.6 EGFR ERBB2 PTEN
15 tenosynovitis of foot and ankle 10.5 AKT1 BIRC5 MMP2
16 large cell carcinoma with rhabdoid phenotype 10.5 BIRC5 EGFR MET
17 her2-receptor negative breast cancer 10.5 EGFR ERBB2
18 myeloid/lymphoid neoplasm associated with pdgfra rearrangement 10.5 BIRC5 EGFR
19 primary malignant melanoma of the conjunctiva 10.5 AKT1 CASP3 MET
20 subglottis verrucous carcinoma 10.5 EGFR ERBB2
21 acquired hemangioma 10.5 EGFR MMP2 MMP9
22 non-distal trisomy 10q 10.5 EGFR MET PPARG
23 estrogen-receptor negative breast cancer 10.5 AKT1 EGFR ERBB2
24 periventricular nodular heterotopia 6 10.5 EGFR MET PTEN
25 rare endometriosis 10.5 BIRC5 MMP2 MMP9
26 endometriosis of uterus 10.5 EGFR ERBB2 PTEN
27 spindle epithelial tumor with thymus-like differentiation tumor 10.5 EGFR MMP2 MMP9
28 chorea, hereditary benign 10.5 MET PPARG PTEN
29 trachea carcinoma in situ 10.5 ERBB2 MET MMP2
30 cystic lymphangioma 10.5 EGFR MMP2 PTEN
31 leucocyte adhesion defect 10.5 MMP2 MMP9
32 integumentary system cancer 10.5 AKT1 CASP3 EGFR
33 postmenopausal atrophic vaginitis 10.4 AKT1 CASP3 CASP8
34 dental caries 10.4 AKT1 ERBB2 MMP2
35 cystadenoma 10.4 AKT1 CASP3 CASP8
36 nasal cavity disease 10.4 AKT1 ERBB2 MMP2
37 early myoclonic encephalopathy 10.4 MMP7 MMP9 PTEN
38 medullomyoblastoma 10.3 AKT1 CASP3 PTEN
39 familial short qt syndrome 10.3 MMP2 MMP7 MMP9
40 septicemic plague 10.3 CASP8 EGFR ERBB2 MMP9
41 kleptomania 10.3 MMP2 MMP7 MMP9
42 tinea profunda 10.3 MMP2 MMP7 MMP9
43 limbic encephalitis 10.3 MMP2 MMP7 MMP9
44 skin tag 10.3 BIRC5 CASP3 MET
45 paroxysmal nocturnal hemoglobinuria 10.3 AKT1 EGFR ERBB2 SERPINB5
46 ovarian brenner tumor 10.3 AKT1 EGFR MET PTEN
47 ladd syndrome 10.2 BIRC5 CASP3 CASP8 MMP2
48 adult astrocytic tumour 10.2 AKT1 EGFR MMP2 PTEN
49 transitional meningioma 10.2 MMP2 MMP9
50 atrophic gastritis 10.2 CASP3 MMP2 MMP9

Graphical network of the top 20 diseases related to Salivary Gland Cancer:



Diseases related to Salivary Gland Cancer

Symptoms & Phenotypes for Salivary Gland Cancer

UMLS symptoms related to Salivary Gland Cancer:


halitosis, snoring

GenomeRNAi Phenotypes related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 9.26 CASP3 EGFR ERBB2
2 Decreased viability with paclitaxel GR00179-A-3 9.26 EGFR
3 Increased cell viability after pRB stimulation GR00230-A-1 8.92 AKT1 EGFR ERBB2 MET

MGI Mouse Phenotypes related to Salivary Gland Cancer:

44 (show all 24)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.5 MET MMP7 MMP9 PPARG PTEN SERPINB5
2 growth/size/body region MP:0005378 10.49 AKT1 CASP3 CASP8 CRTC1 EGFR ERBB2
3 cardiovascular system MP:0005385 10.48 CASP8 EGFR ERBB2 ID1 ISL1 MET
4 homeostasis/metabolism MP:0005376 10.44 AKT1 BIRC5 CASP3 CASP8 CRTC1 EGFR
5 immune system MP:0005387 10.43 AKT1 BIRC5 CASP3 CASP8 CRTC1 EGFR
6 hematopoietic system MP:0005397 10.42 AKT1 BIRC5 CASP3 CASP8 CRTC1 EGFR
7 endocrine/exocrine gland MP:0005379 10.41 PTEN STAT3 TRAF2 AKT1 BIRC5 CASP3
8 mortality/aging MP:0010768 10.41 PTEN SERPINB5 STAT3 TRAF2 AKT1 BIRC5
9 embryo MP:0005380 10.35 CASP8 EGFR ERBB2 ID1 ISL1 MET
10 behavior/neurological MP:0005386 10.31 AKT1 CASP3 CRTC1 ERBB2 ISL1 MET
11 muscle MP:0005369 10.3 AKT1 CASP3 CASP8 EGFR ERBB2 ID1
12 digestive/alimentary MP:0005381 10.28 CASP3 EGFR ERBB2 ID1 ISL1 MET
13 neoplasm MP:0002006 10.25 AKT1 CASP8 EGFR ERBB2 ID1 ISL1
14 adipose tissue MP:0005375 10.22 AKT1 CRTC1 EGFR PPARG PTEN SERPINB5
15 nervous system MP:0003631 10.22 CASP3 CASP8 EGFR ERBB2 ID1 ISL1
16 integument MP:0010771 10.21 STAT3 AKT1 CASP3 CASP8 EGFR ERBB2
17 craniofacial MP:0005382 10.14 CASP3 EGFR ERBB2 ISL1 MET MMP2
18 normal MP:0002873 10.11 SERPINB5 STAT3 AKT1 BIRC5 EGFR ERBB2
19 liver/biliary system MP:0005370 10.1 AKT1 CASP8 EGFR ID1 MET PPARG
20 renal/urinary system MP:0005367 10.06 CASP3 CASP8 EGFR ID1 ISL1 MET
21 reproductive system MP:0005389 10 AKT1 CASP3 CRTC1 EGFR ERBB2 ID1
22 respiratory system MP:0005388 9.9 AKT1 CASP3 CASP8 EGFR ERBB2 ID1
23 skeleton MP:0005390 9.7 AKT1 CASP3 EGFR ERBB2 ID1 ISL1
24 vision/eye MP:0005391 9.36 ID1 ISL1 MET MMP2 MMP7 MMP9

Drugs & Therapeutics for Salivary Gland Cancer

Drugs for Salivary Gland Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 241)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bleomycin Approved Phase 4 11056-06-7 5360373
2 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1
3 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 1
4
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 84093 441203 2767
5
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
6
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
7
Pilocarpine Approved Phase 3,Phase 2 54-71-7, 92-13-7 5910
8
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
11
Doxepin Approved Phase 3 1668-19-5 667477 667468
12
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
13
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
14
Fluorouracil Approved Phase 3,Phase 1 51-21-8 3385
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
16
leucovorin Approved, Nutraceutical Phase 3,Phase 1 58-05-9 143 6006
17 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
18
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
19
Iodine Investigational Phase 3 7553-56-2 807
20 Pharmaceutical Solutions Phase 3
21 Autonomic Agents Phase 3,Phase 2
22 Neurotransmitter Agents Phase 3,Phase 2
23 Peripheral Nervous System Agents Phase 3,Phase 2
24 Analgesics Phase 3,Phase 2
25 Liver Extracts Phase 3,Phase 2,Phase 1
26 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2
27 Antimetabolites Phase 3,Phase 1,Phase 2
28 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
29 Antimitotic Agents Phase 3,Phase 1,Phase 2
30 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
31 Antirheumatic Agents Phase 3,Phase 2
32 Dermatologic Agents Phase 3,Phase 2
33 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
34 Cholinergic Agents Phase 3,Phase 2
35 Adjuvants, Anesthesia Phase 3
36 Analgesics, Opioid Phase 3
37 Anesthetics Phase 3,Phase 2
38 Anesthetics, General Phase 3
39 Anesthetics, Intravenous Phase 3
40 Central Nervous System Depressants Phase 3
41 Narcotics Phase 3
42 Folic Acid Antagonists Phase 3,Phase 1
43 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1
44 Vitamin B Complex Phase 3,Phase 2,Phase 1
45 Antidepressive Agents Phase 3
46 Antidepressive Agents, Tricyclic Phase 3
47 Histamine Antagonists Phase 3
48
Histamine Phosphate Phase 3 51-74-1 65513
49 Psychotropic Drugs Phase 3
50 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 229)

id Name Status NCT ID Phase Drugs
1 Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer Completed NCT00198263 Phase 4
2 A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients Recruiting NCT02948699 Phase 4
3 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
4 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
5 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
6 Hyperbaric Oxygen - a New Treatment Modality in Patients With Radiation Damaged Salivary Gland Tissue Unknown status NCT01606644 Phase 3
7 Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients Completed NCT00168181 Phase 3 Salagen
8 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
9 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
10 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
11 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
12 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
13 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
14 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
15 Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00003139 Phase 3 pilocarpine hydrochloride
16 Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer Recruiting NCT02048254 Phase 3
17 Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors Recruiting NCT02998385 Phase 3 Cisplatin
18 Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma Recruiting NCT01874587 Phase 3
19 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
20 Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer Active, not recruiting NCT01141231 Phase 3
21 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
22 Activity of Sorafenib in Salivary Gland Cancer Unknown status NCT01703455 Phase 2 Sorafenib
23 CO(Mbined Therapy of Malignant) S(Alivary Gland tu)M(Ours With)I(MRT and) c(Arbon Ions): COSMIC Unknown status NCT01154270 Phase 2
24 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
25 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
26 Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00022217 Phase 2 carboplatin;cisplatin-e therapeutic implant;paclitaxel
27 Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Unknown status NCT00052611 Phase 2 celecoxib
28 Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy Unknown status NCT00003856 Phase 2 temoporfin
29 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
30 Treatment of Radiation-induced Fibrosis in the Upper Aerodigestive Tract Cancer by a Combination of Pentoxifylline-tocopherol and Hyperbaric Oxygen Unknown status NCT01822405 Phase 2 pentoxifylline with tocopherol
31 Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) Unknown status NCT00652613 Phase 2
32 A Study of Intensity-modulated Radiotherapy in Patients With Squamous Cell Carcinoma of Unknown Primary (SCCUP) of the Head and Neck Unknown status NCT02112344 Phase 1, Phase 2
33 Iressa Study in Patients With Salivary Gland Cancer Completed NCT00509002 Phase 2 Gefitinib
34 Imatinib Mesylate in Treating Patients With Salivary Gland Cancer Completed NCT00045669 Phase 2 imatinib mesylate
35 Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer Completed NCT00002632 Phase 2 paclitaxel
36 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
37 Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Completed NCT00004163 Phase 2 Trastuzumab
38 Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
39 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed NCT00095563 Phase 2 lapatinib ditosylate
40 A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors Completed NCT01488838 Phase 2 Cisplatin: 40 mg/m2 weekly during radiation
41 A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT00886132 Phase 2 Sunitinib
42 A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT01678105 Phase 2 Dovitinib
43 Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck Completed NCT00077428 Phase 2 bortezomib;doxorubicin hydrochloride
44 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
45 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
46 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
47 Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck Completed NCT00017498 Phase 2 gemcitabine hydrochloride
48 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
49 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
50 SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00095628 Phase 2 ispinesib

Search NIH Clinical Center for Salivary Gland Cancer

Genetic Tests for Salivary Gland Cancer

Genetic tests related to Salivary Gland Cancer:

id Genetic test Affiliating Genes
1 Salivary Gland Neoplasm 29

Anatomical Context for Salivary Gland Cancer

MalaCards organs/tissues related to Salivary Gland Cancer:

39
Salivary Gland, Lung, Testes, Brain, Liver, Lymph Node, Thyroid

Publications for Salivary Gland Cancer

Articles related to Salivary Gland Cancer:

(show top 50) (show all 130)
id Title Authors Year
1
Effective nasal mask ventilation of a difficult airway in a patient with advanced salivary gland cancer. ( 28494881 )
2017
2
The rising incidence of major salivary gland cancer in the United States. ( 28346649 )
2017
3
Silymarin and its active component silibinin act as novel therapeutic alternatives for salivary gland cancer by targeting the ERK1/2-Bim signaling cascade. ( 28401485 )
2017
4
Nomograms for predicting long-term overall survival and cancer-specific survival in patients with major salivary gland cancer: a population-based study. ( 28160551 )
2017
5
Androgen Receptor Signaling in Salivary Gland Cancer. ( 28208703 )
2017
6
A Case-Control Study of Risk Factors for Salivary Gland Cancer in Canada. ( 28133481 )
2017
7
Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). ( 28102887 )
2017
8
Heterogeneous impact of smoking on major salivary gland cancer according to histopathological subtype: A case-control study. ( 28881386 )
2017
9
Immunohistochemical and molecular profile of salivary gland cancer in children. ( 28139061 )
2017
10
Develop and validation a nomogram to predict the recurrent probability in patients with major salivary gland cancer. ( 28819427 )
2017
11
Cytomegalovirus induces Interleukin-6 mediated inflammatory response in salivary gland cancer. ( 28039719 )
2016
12
Targeting ID2 expression triggers a more differentiated phenotype and reduces aggressiveness in human salivary gland cancer cells. ( 27364596 )
2016
13
High-grade histology as predictor of early distant metastases and decreased disease-free survival in salivary gland cancer irrespective of tumor subtype. ( 26841273 )
2016
14
The MMP-2 and MMP-9 promoter polymorphisms and susceptibility to salivary gland cancer. ( 27569079 )
2016
15
(A+)-Gossypol induces apoptosis and autophagy in head and neck carcinoma cell lines and inhibits the growth of transplanted salivary gland cancer cells in BALB/c mice. ( 27670669 )
2016
16
Incidence and risk factors of late recurrence in patients with salivary gland cancer. ( 27960047 )
2016
17
ID1 Controls Aggressiveness of Salivary Gland Cancer Cells via Crosstalk of IGF and AKT Pathways. ( 27466488 )
2016
18
Unmet needs for patients with salivary gland cancer. ( 27377424 )
2016
19
Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature. ( 28006087 )
2016
20
An epidemiological evaluation of salivary gland cancer in the Netherlands (1989-2010). ( 25454260 )
2015
21
Diagnostic utility of phosphorylated signal transducer and activator of transcription 5 immunostaining in the diagnosis of mammary analogue secretory carcinoma of the salivary gland: A comparative study of salivary gland cancers. ( 26252941 )
2015
22
Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer. ( 26661925 )
2015
23
Convallaria keiskei as a novel therapeutic alternative for salivary gland cancer treatment by targeting myeloid cell leukemia-1. ( 25914292 )
2015
24
Increased risk of salivary gland cancer among women with a previous cancer diagnosis. ( 25581457 )
2015
25
Outcomes and prognostic factors in modern era management of major salivary gland cancer. ( 26033470 )
2015
26
Salivary gland cancer risk and BRCA gene mutations may be linked, study finds. ( 25577819 )
2014
27
Familial predisposition for salivary gland cancer in Finland. ( 24701124 )
2014
28
Salivary Gland Cancer in BRCA-Positive Families : A Retrospective Review. ( 25257187 )
2014
29
The Impact of Demographic and Socioeconomic Factors on Major Salivary Gland Cancer Survival. ( 24647644 )
2014
30
Retracted: the oncogenic effects of constitutive Stat3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac. ( 25610927 )
2014
31
Racial and Ethnic Disparities in Salivary Gland Cancer Survival. ( 24744112 )
2014
32
Overview of major salivary gland cancer surgery in Ontario (2003A?2010). ( 25492404 )
2014
33
Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. ( 23242174 )
2013
34
Targeting Id1 reduces proliferation and invasion in aggressive human salivary gland cancer cells. ( 23517130 )
2013
35
Risk of salivary gland cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. ( 22836059 )
2013
36
Predictors of cervical lymph node metastasis in salivary gland cancer. ( 23780687 )
2013
37
Salivary gland cancer: an update on present and emerging therapies. ( 23714518 )
2013
38
Expression and function of CXCR4 in human salivary gland cancers. ( 22847686 )
2013
39
The Justy mutant mouse strain produces a spontaneous murine model of salivary gland cancer with myoepithelial and basal cell differentiation. ( 23608756 )
2013
40
Salivary gland cancer stem cells. ( 23810400 )
2013
41
Antitumour effect of valproic acid against salivary gland cancer in vitro and in vivo. ( 24398788 )
2013
42
The prognostic impact of human leukocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases. ( 23611358 )
2013
43
Paediatric salivary gland cancer in Finland. ( 22721526 )
2012
44
WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer. ( 22399636 )
2012
45
Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. ( 22240798 )
2012
46
EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. ( 22154363 )
2012
47
Probing the role of mesenchymal stem cells in salivary gland cancer on biomimetic microdevices. ( 22499505 )
2012
48
Recurrent salivary gland cancer. ( 22215326 )
2012
49
Prognostic significance of RB1-inducible coiled-coil 1 in salivary gland cancers. ( 21717524 )
2012
50
The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. ( 22445095 )
2012

Variations for Salivary Gland Cancer

Expression for Salivary Gland Cancer

Search GEO for disease gene expression data for Salivary Gland Cancer.

Pathways for Salivary Gland Cancer

Pathways related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 103)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.12 AKT1 BIRC5 CASP3 CASP8 EGFR ERBB2
2
Show member pathways
13.94 AKT1 CASP3 CASP8 EGFR MET MMP2
3
Show member pathways
13.58 AKT1 EGFR ERBB2 MET MMP2 MMP9
4
Show member pathways
13.48 AKT1 CASP3 EGFR MMP2 MMP7 MMP9
5
Show member pathways
13.48 AKT1 CASP3 EGFR ERBB2 MET PTEN
6
Show member pathways
13.38 AKT1 CASP3 CASP8 EGFR ERBB2 MET
7
Show member pathways
13.36 AKT1 BIRC5 CASP3 EGFR ERBB2 MET
8
Show member pathways
13.35 AKT1 CASP3 CASP8 EGFR ERBB2 MET
9
Show member pathways
12.97 AKT1 EGFR ERBB2 MET PTEN STAT3
10
Show member pathways
12.96 AKT1 EGFR ERBB2 MET PTEN STAT3
11
Show member pathways
12.95 AKT1 CASP3 CASP8 MMP9 TRAF2
12
Show member pathways
12.93 AKT1 CASP3 CASP8 EGFR MET TRAF2
13
Show member pathways
12.88 AKT1 BIRC5 CASP3 CASP8 TRAF2
14
Show member pathways
12.87 AKT1 CASP3 CASP8 STAT3 TRAF2
15
Show member pathways
12.86 AKT1 BIRC5 PTEN STAT3 TRAF2
16
Show member pathways
12.86 AKT1 CASP3 ERBB2 MET PTEN STAT3
17
Show member pathways
12.8 AKT1 EGFR ERBB2 MET PTEN
18
Show member pathways
12.79 AKT1 CASP3 CASP8 EGFR MMP2 PTEN
19 12.78 AKT1 CASP3 CASP8 EGFR TRAF2
20 12.75 AKT1 CASP3 CASP8 EGFR MAML2 MET
21
Show member pathways
12.73 AKT1 CASP3 EGFR STAT3 TRAF2
22
Show member pathways
12.66 AKT1 BIRC5 EGFR ERBB2 MMP2 STAT3
23
Show member pathways
12.57 AKT1 EGFR ERBB2 MET PTEN
24
Show member pathways
12.57 AKT1 CASP3 CASP8 EGFR ERBB2 STAT3
25
Show member pathways
12.55 AKT1 CASP3 ERBB2 PTEN STAT3
26
Show member pathways
12.54 AKT1 BIRC5 CASP3 EGFR ERBB2 MET
27
Show member pathways
12.5 AKT1 CASP3 CASP8 EGFR ERBB2 MET
28
Show member pathways
12.47 AKT1 BIRC5 MET PTEN STAT3
29
Show member pathways
12.44 CASP3 CASP8 PTEN SERPINB5
30 12.4 CASP3 EGFR ERBB2 MET MMP9 PTEN
31
Show member pathways
12.39 AKT1 EGFR ERBB2 PPARG
32
Show member pathways
12.38 AKT1 EGFR ERBB2 STAT3
33
Show member pathways
12.36 AKT1 CASP3 CASP8 TRAF2
34 12.36 CASP3 CASP8 STAT3 TRAF2
35
Show member pathways
12.34 AKT1 CASP3 CASP8 TRAF2
36
Show member pathways
12.33 AKT1 CASP3 CASP8 PTEN
37
Show member pathways
12.33 AKT1 CASP3 CASP8 MMP9 STAT3 TRAF2
38
Show member pathways
12.32 AKT1 CASP3 CASP8 STAT3
39 12.32 BIRC5 CASP3 CASP8 SERPINB5 TRAF2
40
Show member pathways
12.32 AKT1 CASP3 EGFR ERBB2 MET PTEN
41
Show member pathways
12.29 AKT1 CASP3 PPARG STAT3
42 12.26 AKT1 EGFR ERBB2 PTEN STAT3
43 12.22 AKT1 CASP3 CASP8 EGFR PTEN
44
Show member pathways
12.21 AKT1 EGFR ERBB2 PTEN STAT3
45
Show member pathways
12.2 AKT1 CASP3 CASP8 TRAF2
46 12.17 AKT1 CASP3 CRTC1 STAT3
47 12.17 AKT1 CASP3 EGFR ERBB2 MET MMP2
48 12.16 AKT1 ID1 ISL1 STAT3
49
Show member pathways
12.15 AKT1 EGFR PTEN STAT3
50 12.14 EGFR MET MMP2 PTEN SERPINB5

GO Terms for Salivary Gland Cancer

Cellular components related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.86 AKT1 BIRC5 CASP3 CASP8 CRTC1 EGFR
2 membrane raft GO:0045121 9.56 CASP3 CASP8 EGFR TRAF2
3 nucleoplasm GO:0005654 9.4 AKT1 BIRC5 CASP3 CASP8 CRTC1 ID1
4 death-inducing signaling complex GO:0031264 9.16 CASP3 CASP8

Biological processes related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

(show all 45)
id Name GO ID Score Top Affiliating Genes
1 aging GO:0007568 9.95 AKT1 MMP7 PTEN STAT3
2 positive regulation of protein phosphorylation GO:0001934 9.93 AKT1 EGFR ERBB2 MMP9
3 cell proliferation GO:0008283 9.93 AKT1 EGFR ERBB2 MET PTEN STAT3
4 cellular response to insulin stimulus GO:0032869 9.87 AKT1 PPARG PTEN
5 positive regulation of cell growth GO:0030307 9.86 AKT1 EGFR ERBB2
6 extracellular matrix disassembly GO:0022617 9.86 MMP2 MMP7 MMP9
7 positive regulation of epithelial cell proliferation GO:0050679 9.85 EGFR ERBB2 ID1
8 collagen catabolic process GO:0030574 9.85 MMP2 MMP7 MMP9
9 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.85 AKT1 PPARG PTEN TRAF2
10 cellular response to growth factor stimulus GO:0071363 9.83 AKT1 EGFR ERBB2
11 negative regulation of neuron death GO:1901215 9.82 AKT1 STAT3 TRAF2
12 learning or memory GO:0007611 9.82 CASP3 EGFR PTEN
13 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.81 CASP3 CASP8 PPARG TRAF2
14 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.8 AKT1 EGFR ERBB2 MET
15 heart development GO:0007507 9.8 CASP3 ERBB2 ID1 ISL1 PPARG PTEN
16 execution phase of apoptosis GO:0097194 9.79 AKT1 CASP3 CASP8
17 cellular response to nerve growth factor stimulus GO:1990090 9.78 AKT1 ID1 PTEN
18 cellular response to mechanical stimulus GO:0071260 9.78 AKT1 CASP8 EGFR MMP7
19 response to antibiotic GO:0046677 9.77 CASP3 CASP8 ID1
20 phosphatidylinositol-mediated signaling GO:0048015 9.77 AKT1 EGFR ERBB2 MET PTEN
21 cellular response to reactive oxygen species GO:0034614 9.76 AKT1 EGFR MMP9
22 cellular response to cadmium ion GO:0071276 9.73 AKT1 EGFR MMP9
23 cellular response to organic cyclic compound GO:0071407 9.73 AKT1 CASP3 CASP8 STAT3
24 positive regulation of DNA binding GO:0043388 9.71 ISL1 MMP9 PPARG
25 cellular response to epidermal growth factor stimulus GO:0071364 9.71 AKT1 EGFR ERBB2 ID1
26 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.7 CASP8 TRAF2
27 regulation of necroptotic process GO:0060544 9.69 CASP8 TRAF2
28 endothelial cell morphogenesis GO:0001886 9.68 ID1 MET
29 cellular response to leptin stimulus GO:0044320 9.68 PTEN STAT3
30 negative regulation of cell size GO:0045792 9.68 AKT1 PTEN
31 death-inducing signaling complex assembly GO:0071550 9.67 CASP8 TRAF2
32 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.66 AKT1 EGFR
33 response to estradiol GO:0032355 9.65 CASP3 CASP8 EGFR PTEN STAT3
34 response to cobalt ion GO:0032025 9.64 CASP3 CASP8
35 negative regulation of protein homodimerization activity GO:0090074 9.62 ID1 ISL1
36 cellular response to decreased oxygen levels GO:0036294 9.62 AKT1 PTEN
37 response to UV-A GO:0070141 9.58 AKT1 EGFR
38 positive regulation of I-kappaB phosphorylation GO:1903721 9.57 AKT1 TRAF2
39 negative regulation of apoptotic process GO:0043066 9.56 AKT1 BIRC5 CASP3 EGFR ID1 MMP9
40 response to organic substance GO:0010033 9.55 AKT1 CASP3 PPARG PTEN STAT3
41 response to organic cyclic compound GO:0014070 9.1 CASP3 EGFR ID1 PPARG PTEN STAT3
42 apoptotic process GO:0006915 10.14 AKT1 BIRC5 CASP3 CASP8 PTEN TRAF2
43 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.13 AKT1 CRTC1 EGFR ISL1 MAML2 MET
44 positive regulation of apoptotic process GO:0043065 10.03 AKT1 CASP3 MMP9 PPARG PTEN
45 positive regulation of cell proliferation GO:0008284 10 BIRC5 EGFR ISL1 PTEN STAT3

Molecular functions related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.8 AKT1 EGFR PTEN STAT3 TRAF2
2 protein dimerization activity GO:0046983 9.76 ERBB2 ID1 STAT3 TSC22D1
3 enzyme binding GO:0019899 9.73 AKT1 BIRC5 EGFR PPARG PTEN TRAF2
4 identical protein binding GO:0042802 9.65 AKT1 BIRC5 CASP8 EGFR ERBB2 MMP9
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.61 EGFR ERBB2 MET
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.54 EGFR ERBB2 MET
7 cysteine-type endopeptidase activity involved in execution phase of apoptosis GO:0097200 9.51 CASP3 CASP8
8 cysteine-type endopeptidase activity involved in apoptotic process GO:0097153 9.49 CASP3 CASP8
9 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.48 EGFR ERBB2
10 nitric-oxide synthase regulator activity GO:0030235 9.32 AKT1 EGFR
11 protein phosphatase binding GO:0019903 9.1 EGFR ERBB2 MET PPARG STAT3 TRAF2
12 protein binding GO:0005515 10.13 AKT1 BIRC5 CASP3 CASP8 CRTC1 EGFR

Sources for Salivary Gland Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....